CFTR and cystic fibrosis: Recently, a new drug composed of the CFTR modulators elexacaftor, tezacaftor, and ivacaftor (ETI to indicate the triple combination) has achieved a breakthrough in the management of CF disease in patients carrying one or two F508del alleles [24,25].